FDA approves adalimumab-fkjp
medwireNews: The US FDA has approved another adalimumab biosimilar – adalimumab-fkjp – for the treatment of various rheumatic diseases.
Similar to the reference product, adalimumab-fkjp is approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, as well as plaque psoriasis and inflammatory bowel disease.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature Group